Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Show More...
-
Website https://www.replimune.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 8.98 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-03 2011-03 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 TTM Earnings Per Share USD -0.36 -0.92 -1.33 -1.28 Dividends USD Payout Ratio % * Shares Mil 31.0 31.0 23.0 32.0 Book Value Per Share * USD 4.52 5.39 Free Cash Flow Per Share * USD -0.77 Return on Assets % -33.76 -44.79 -28.1 -21.61 Financial Leverage (Average) 1.08 1.12 1.27 Return on Equity % -81.38 -31.18 -25.52 Return on Invested Capital % -82.57 -33.79 -22.23 Interest Coverage Current Ratio 11.29 12.53 14.26 13.43 Quick Ratio 11.08 12.38 13.89 13.06 Debt/Equity 0.2